BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rangnekar AS, Fontana RJ. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther. 2012;36:104-114. [PMID: 22612303 DOI: 10.1111/j.1365-2036.2012.05145.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ma P, Luo Z, Qian J, Yan Z, Zhang L, Martin L, Wang Z, Xia H, Yu F, Jiang W. Decreased ratio of influenza-specific IgG versus IgM in response to influenza vaccination in antiretroviral-treated HIV-infected African Americans compared to Caucasians, and its direct correlation with the percentages of peripheral Tfh cells. Vaccine 2020;38:1998-2004. [PMID: 31948820 DOI: 10.1016/j.vaccine.2020.01.002] [Reference Citation Analysis]
2 Huang Y, Li MH, Hou M, Xie Y. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. Hepatobiliary Pancreat Dis Int 2017;16:470-9. [PMID: 28992878 DOI: 10.1016/S1499-3872(17)60044-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
3 Sims OT, Pollio DE, Hong BA, North CS. Racial Disparities in Hepatitis C Treatment Eligibility. Ann Hepatol 2017;16:530-7. [PMID: 28611273 DOI: 10.5604/01.3001.0010.0282] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
4 Tan YW, Tao Y, Liu LG, Ye Y, Zhou XB, Chen L, He C. Epidemiological features of chronic hepatitis C infection caused by remunerated blood donors: A nearly 27-year period survey. World J Gastroenterol 2018; 24(11): 1250-1258 [PMID: 29568205 DOI: 10.3748/wjg.v24.i11.1250] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Benhammou JN, Dong TS, May FP, Kawamoto J, Dixit R, Jackson S, Dixit V, Bhattacharya D, Han SB, Pisegna JR. Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. Pharmacol Res Perspect. 2018;6:e00379. [PMID: 29484189 DOI: 10.1002/prp2.379] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
6 Kao JH, Ahn SH, Chien RN, Cho M, Chuang WL, Jeong SH, Liu CH, Paik SW. Urgency to treat patients with chronic hepatitis C in Asia. J Gastroenterol Hepatol 2017;32:966-74. [PMID: 28005275 DOI: 10.1111/jgh.13709] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
7 Yu JH, Lee JI, Lee KS, Kim JK. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C. Virol J 2017;14:164. [PMID: 28836992 DOI: 10.1186/s12985-017-0826-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Du L, Tang H. An insight into the molecular characteristics of hepatitis C virus for clinicians. Saudi Med J 2016;37:483-91. [PMID: 27146609 DOI: 10.15537/smj.2016.5.14178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Zhao YJ, Khoo AL, Lin L, Teng M, Koh CJ, Lim SG, Lim BP, Dan YY. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C. J Gastroenterol Hepatol 2016;31:1628-37. [PMID: 26990023 DOI: 10.1111/jgh.13341] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
10 Li Y, Yang L, Sha K, Liu T, Zhang L. Correlation of interferon-lambda 4 ss469415590 with the hepatitis C virus treatment response and its comparison with interleukin 28b polymorphisms in predicting a sustained virological response: a meta-analysis. Int J Infect Dis 2016;53:52-8. [PMID: 27810523 DOI: 10.1016/j.ijid.2016.10.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
11 Malov IV, Malov SI, Savilov ED, Gantulga D, Stepanenko LA, Ogarkov OB, Nyamkhuu D, Aitov KA, Nyamdawa P, Kolesnikov SI. Population Polymorphism of IFNL3 and IFNL4 Genes of Type 3 Interferon Associated with Spontaneous Clearance of Hepatitis C Virus in Representatives of Caucasian and Mongoloid Races. Bull Exp Biol Med 2016;161:404-7. [PMID: 27492404 DOI: 10.1007/s10517-016-3425-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Liu CH, Sheng WH, Sun HY, Hsieh SM, Lo YC, Liu CJ, Su TH, Yang HC, Liu WC, Chen PJ, Chen DS, Hung CC, Kao JH. Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. Sci Rep 2015;5:17410. [PMID: 26616669 DOI: 10.1038/srep17410] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
13 Coppola N, Pisaturo M, Sagnelli C, Onorato L, Sagnelli E. Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases 2015; 3(9): 807-822 [PMID: 26380828 DOI: 10.12998/wjcc.v3.i9.807] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
14 Dan YY, Lim SG. Hepatitis C: An Eastern Perspective. Gastroenterol Clin North Am. 2015;44:793-805. [PMID: 26600220 DOI: 10.1016/j.gtc.2015.07.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
15 Lim SG, Dan YY. A 2015 roadmap for the management of hepatitis C virus infections in Asia. Korean J Intern Med 2015;30:423-33. [PMID: 26161008 DOI: 10.3904/kjim.2015.30.4.423] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
16 Hu CC, Lin CL, Chang LC, Chien CH, Chen LW, Liu CJ, Chien RN. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study. BMC Infect Dis 2015;15:156. [PMID: 25888020 DOI: 10.1186/s12879-015-0888-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
17 Bichoupan K, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Perumalswami PV, Schiano TD, Odin JA, Liu L, Moskowitz AJ, Dieterich DT, Branch AD. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology 2014;60:1187-95. [PMID: 25065814 DOI: 10.1002/hep.27340] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
18 Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African Americans. Am J Gastroenterol 2014;109:1576-84; quiz 1575, 1585. [PMID: 25178700 DOI: 10.1038/ajg.2014.243] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
19 Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014;9:2051-67. [PMID: 24812506 DOI: 10.2147/IJN.S41822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
20 Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN. Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol 2014; 20(11): 2839-2853 [PMID: 24659876 DOI: 10.3748/wjg.v20.i11.2839] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
21 Liu T, Sha K, Yang L, Wang Y, Zhang L, Liu X, Yang F. IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis. PLoS One 2014;9:e91316. [PMID: 24642705 DOI: 10.1371/journal.pone.0091316] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
22 Palmieri O, Ippolito AM, Margaglione M, Valvano MR, Gioffreda D, Fasano M, D'Andrea G, Corritore G, Milella M, Andriulli N, Morisco F, Giannitrapani L, Latiano A, Fontana R, Gatti P, Tundo P, Barone M, Cozzolongo R, Santantonio T, Andriulli A. Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance. Liver Int 2014;34:1369-77. [PMID: 25283962 DOI: 10.1111/liv.12411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
23 Croagh C, Lubel J. Advances in the management of hepatitis C: Advances in hepatitis C. Intern Med J 2013;43:1265-71. [DOI: 10.1111/imj.12304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
24 Covolo L, Bibert S, Donato F, Bochud P, Lagging M, Negro F, Fattovich G. The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. Aliment Pharmacol Ther 2014;39:322-30. [DOI: 10.1111/apt.12568] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
25 Kwon JH, Bae SH, Lee YJ, Lee J, Kim YS, Hwang JS, Tak WY, Jang JW, Lee BS, Lee JS, Lee CK, Baik SK, Park NH, Lee TH, Kim DJ, Choi J, Shin J, Yim HW. The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial. Hepatol Int 2013;7:1000-9. [DOI: 10.1007/s12072-013-9472-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
26 Zhang L, Gwinn M, Hu DJ. Viral hepatitis C gets personal--the value of human genomics to public health. Public Health Genomics. 2013;16:192-197. [PMID: 23859951 DOI: 10.1159/000352014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
27 Liu C, Kao J. IL28B Genotype on HCV Infection in Asia. Curr Hepatitis Rep 2013;12:149-56. [DOI: 10.1007/s11901-013-0176-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Rempel JD, Uhanova J. Hepatitis C virus in American Indian/Alaskan Native and Aboriginal peoples of North America. Viruses 2012;4:3912-31. [PMID: 23342378 DOI: 10.3390/v4123912] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
29 Rangnekar AS, Fontana RJ. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat. 2013;20:377-384. [PMID: 23647954 DOI: 10.1111/jvh.12039] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]